Assessment of Needs
This webinar is designed for practitioners in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs who are new to the field of HIV patient care, and other clinicians caring for people with HIV, including advanced practitioners, residents, and infectious diseases fellows. It is also relevant for clinicians who are interested in a review of the field. In the webinar, experts in the field will describe the mechanism of action of antiretroviral drugs, initiating antiretroviral therapy, and primary care for people with HIV.
At the end of this webinar, participants will be able to:
- Basic mechanisms of antiretroviral therapy
- Antiretroviral regimens based on patient parameters
- Screening and managing comorbidities in persons with HIV
View the on-demand recording of our webinar on the Fundamentals of HIV Infections and Application of Antiretroviral Therapy, presented on September 29, 2021, by Michael S. Saag, MD of the University of Alabama at Birmingham.
Who Should Attend
This webinar is designed for clinical decision makers who are in training, new to, or are interested in a review of HIV patient care, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Though attendance for the 2022 Ryan White HIV/AIDS CLINICAL CONFERENCE is limited to HIV physicians, nurse practitioners, physician assistants, and primary clinical decision makers in Ryan White HIV/AIDS Program (RWHAP)-funded clinics and programs, registration for this webinar is open to all.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, September 28, 2022, 8:00 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at email@example.com or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.
The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc and ViiV Healthcare. (Updated 07/19/22)
Dr Thompson’s institution has received research grants from Gilead Sciences, Inc, Merck Sharp Dohme, and ViiV Healthcare. She has served on advisory and data safety monitoring boards for Excision Biotherapeutics. (Updated 07/19/22)
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 07/19/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 07/19/22)
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Point
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.
These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.